Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AAPD vs COCP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

COCP Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 7–1 Matrix Metrics)

COCP Overall Winner 6-Pillar Tally: AAPD 0 – 4 COCP (2 Tie) Matrix Metrics: AAPD 1 – 7 COCP

As of Nov 16, 2026, Cocrystal Pharma, Inc. (COCP) is the stronger overall head-to-head candidate over Direxion Daily AAPL Bear 1X Shares (AAPD) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AAPD carries a Unified Composite Score of 43.5/100 (HOLD) at $9.75 (N/M Forward P/E, N/A operating margin), whereas COCP carries 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin).

  • Technical & Structure Timing Caution: AAPD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4); meanwhile COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AAPD vs COCP
AAPD NASDAQ
Direxion Daily AAPL Bear 1X Shares
Institutional Equity
$9.75
+1.35% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.55β · 27% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 36.0 Fund 49.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.5%), weak momentum, RSI 43
RSI-14: 43.4 · SMA20: $9.91 · SMA50: $10.14
COCP NASDAQ Head-to-Head Winner
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap $19.6M
TTM Revenue $330,000
Forward P/E N/M
Beta / 30D Vol 1.04β · 54% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 51.0 Fund 48.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $1.00 · SMA50: $1.08

6-Pillar Scorecard Institutional Category Breakdown (AAPD 0 – 4 COCP)

Columns: Metric · AAPD · COCP
1. Valuation Multiples COCP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 49.7x
2. Growth & Scale COCP
Revenue Growth (YoY) N/A +26.9%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $330,000
Market Cap N/A $19.6M
3. Profitability & Quality COCP
Gross Margin N/A N/A
Operating Margin N/A -3063.6%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -311.7%
4. Balance Sheet & Cash Flow COCP
Cash Generation (TTM) N/A -$7.6M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $3.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 32.2% (12th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AAPD (1) vs COCP (7)
Institutional Metric AAPD COCP Criterion Row Edge
Market Capitalization
Scale
N/A $19.6M Larger Scale COCP
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +26.9% Higher Growth COCP
Operating Margin (TTM)
Profitability
N/A -3063.6% Higher Margin COCP
Net Profit Margin
Profitability
N/A 0.0% Higher Margin COCP
Return on Equity (ROE)
Capital Efficiency
N/A -311.7% Higher ROE COCP
52-Week Range Position
Momentum
5% ($10–$15) 19% ($1–$2) Stronger Trend COCP
Beta / 30D Volatility
Risk Regime
-0.55β · 27% Vol 1.04β · 54% Vol Lower Realized Risk AAPD
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 47.1 / 100 (HOLD) Higher Composite COCP
Trailing 12M Revenue (USD)
Operating Scale
N/A $330,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 49.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$7.6M ($3.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon COCP +0.49 pp
AAPD: -2.5% · COCP: -2.01%
3M Horizon COCP +5.57 pp
AAPD: -13.02% · COCP: -7.45%
6M Horizon COCP +2.7 pp
AAPD: -18.0% · COCP: -15.3%
1Y Horizon COCP +22.5 pp
AAPD: -25.46% · COCP: -2.96%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AAPD vs COCP. Trailing 12-month operating profitability (AAPD N/A vs COCP -3063.6%) and valuation multiples (AAPD N/M vs COCP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AAPD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
COCP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$330,000
Gross MarginN/A
Op. Margin-3063.6%
ROE / Fwd P/E-311.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AAPD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 32.2%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AAPD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
COCP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AAPD Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
COCP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $19.6M market capitalization and -3063.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AAPD vs COCP Key Questions & Quantitative Answers

As of Nov 16, 2026, Cocrystal Pharma, Inc. (COCP) is the stronger overall head-to-head candidate over Direxion Daily AAPL Bear 1X Shares (AAPD) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AAPD carries a Unified Composite Score of 43.5/100 (HOLD) at $9.75 (N/M Forward P/E, N/A operating margin), whereas COCP carries 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin). Technical & Structure Timing Caution: AAPD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4); meanwhile COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

COCP leads the Growth & Scale pillar: AAPD posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with COCP at +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin). On trailing 12-month operating scale, AAPD generates N/A in USD-normalized revenue versus $330,000 for COCP. In operating R&D and SG&A reinvestment, AAPD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCP.

COCP screens cheaper on headline valuation multiples. AAPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 49.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AAPD (N/A ROE) versus COCP (-311.7% ROE) capital efficiency.

In options market volatility and institutional positioning, AAPD carries 32.2% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.55β · 27% Vol realized risk). By comparison, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.